long intergenic non-protein coding RNA 1620Genealiases: C20orf62 · dJ1013A22.3
Q-omics provides the consensus-scored LINC01620 profile across patient tissues and cancer cell-line models. LINC01620 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, LINC01620 is differentially expressed in 5, with the highest sampling consensus in KIRC. Additionally, LINC01620 RNA expression shows 6,676 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight SKCM, KIRC, and STAD as cancer lineages where LINC01620 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01620 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01620 survival associations across molecular data types. LINC01620 RNA expression shows survival associations in the most cancer types (14), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01620 RNA expression–survival associations across cancer types. High LINC01620 expression shows unfavorable associations in ACC, MESO, LUAD, LUSC and READ, but favorable associations in SKCM. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .011). Together, the overview and detailed table identify SKCM as the clearest survival context for LINC01620 RNA expression.
This table summarizes LINC01620 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01620. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01620 shows lower tumor expression in CHOL, LUAD and LUSC and higher tumor expression in KIRC and HNSC. The KIRC box plot shows higher LINC01620 RNA expression in tumor versus normal tissue (log2 FC = +0.052, t-test p < 0.001).
This table shows molecular features associated with LINC01620 in patient tissues and cancer cell lines. In patient samples, LINC01620 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, LINC01620 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE.
